Mandate

Vinge Advises Sunstone Capital on the Investment in CMC Contrast

February 27, 2008

Vinge advises Sunstone Capital on the investment in CMC Contrast. CMC Contrast develops the CMC 001 product. The product can be found on the market for international pharmaceuticals. The investment will contribute to further the development of the product and continued clinical studies.

Sunstone Capital is represented by partner Johan Winnerblad joined by associate Jonas Bergström.

Related

Vinge has advised Sveafastigheter in connection with its uplisting to Nasdaq Stockholm

Vinge has advised Sveafastigheter AB (publ) in connection with its list change from Nasdaq First North Premier Growth Market to Nasdaq Stockholm. The prospectus was published on 13 June 2025 and the trading on Nasdaq Stockholm commenced on 18 June 2025.
June 18, 2025

Vinge advises Bridgepoint in its acquisition of Safe Life

Vinge advises Bridgepoint in its agreement to acquire a significant controlling stake in Safe Life, a global leader in the distribution of automated external defibrillators (AEDs), in a transaction that values the company at c. €500 million.
June 16, 2025

Vinge advises Armada Investment AG on its investment in Studsvik

Armada Investment AG, the Zurich-based entrepreneurial investment firm led by Daniel S. Aegerter, has increased its shareholding in Studsvik to 29.9% of outstanding shares. The investment builds on Armada's initial 9.9% stake acquired in February 2025. The shares of Studsvik are admitted to trading on Nasdaq Stockholm. Armada has invested across the nuclear supply chain for over a decade, with portfolio companies including Oklo, Commonwealth Fusion Systems, Proxima Fusion, Last Energy, and Blykalla.
June 16, 2025